Loading...
Loading...
GRPH| Name | Value |
|---|---|
| Revenues | 10.2M |
| Cost of Revenue | 0.1M |
| Gross Profit | 10.1M |
| Operating Expense | 14.5M |
| Operating I/L | -14.6M |
| Other Income/Expense | -8.3M |
| Interest Income | 2.6M |
| Pretax | -22.9M |
| Income Tax Expense | -31.1M |
| Net Income/Loss | -22.9M |
Graphite Bio, Inc. is a clinical-stage gene editing company based in the United States. The company focuses on developing therapies for serious and life-threatening diseases. Its product portfolio includes GPH101, a gene-edited autologous hematopoietic stem cell product candidate for sickle cell disease; GPH201 for X-linked severe combined immunodeficiency syndrome; and GPH301 for Gaucher disease. These products aim to directly correct genetic mutations and address enzyme deficiencies. Graphite Bio, Inc. generates revenue through the development and potential commercialization of these gene-edited therapies, offering hope for patients with these debilitating conditions.
